Discovery of a novel IL-15 based protein with improved developability and efficacy for cancer immunotherapy.

ABSTRACT: Interleukin-15 (IL-15) can promote both innate and adaptive immune reactions by stimulating CD8⁺/CD4⁺ T cells and natural killer cells (NK) while showing no effect in activating T-regulatory (Treg) cells or inducing activation-associated death among effector T cells and NK cells. Thus, IL-15 is considered as one of the most promising molecules for antitumor immune therapy. To improve the drug-like properties of natural IL-15, we create an IL-15-based molecule, named P22339, with the following characteristics: 1) building a complex of IL-15 and the Sushi domain of IL-15 receptor α chain to enhance the agonist activity of IL-15 via transpresentation; 2) through a rational structure-based design, creating a disulfide bond linking the IL-15/Sushi domain complex with an Ig

SUBMITTER: Hu Q 

PROVIDER: S-EPMC5955975 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature